Thrombotic microangiopathy (TMA) represents a severe clinical condition characterized by endothelial injury, microvascular thrombosis, and multiorgan dysfunction. In pediatric patients with renal involvement, TMA is a significant contributor to morbidity and mortality, demanding prompt recognition and tailored management strategies. This review provides a comprehensive analysis of TMA within the context of pediatric nephrology, encompassing its diverse etiologies, including atypical hemolytic uremic syndrome (aHUS), shiga toxin-associated HUS, and secondary TMA linked to systemic conditions or therapeutic interventions. The article highlights recent advancements in diagnostic techniques, with a focus on biomarkers and genetic profiling, which have enhanced the precision of TMA classification and risk stratification. Furthermore, it examines evolving therapeutic modalities, such as complement inhibitors, alongside traditional interventions like plasma exchange and supportive care. By synthesizing current evidence, this review aims to elucidate the pathophysiological underpinnings of TMA, identify critical gaps in research, and propose future directions to optimize outcomes in renal pediatric patients. The insights offered are poised to inform clinical practice and stimulate further investigations into this complex and life-threatening condition.